Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 10/20 | 1.00 |
| ▸ | EGFR | P00533 | 12/20 | 0.76 |
| ▸ | ERBB4 | Q15303 | 6/20 | 0.76 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.63 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | CLK1 | P49759 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8596174 | 0.99 | ERBB2 (0.98) | ERBB2EGFRERBB4KDREPHA2 | |
| SCHEMBL8595567 | 0.92 | ERBB2 (0.86) | ERBB2EGFRERBB4KDREPHA2 | |
| Hydrochloric Acid SCHEMBL8558936 | 0.91 | ERBB2 (0.84) | ERBB2EGFRERBB4KDREPHA2 | |
| SCHEMBL8560791 | 0.91 | ERBB2 (0.84) | ERBB2EGFRERBB4KDREPHA2 | |
| Hydrochloric Acid SCHEMBL8895186 | 0.91 | ERBB2 (0.83) | ERBB2EGFRERBB4KDREPHA2 | |
| SCHEMBL9910677 | 0.86 | ERBB2 (0.75) | ERBB2EGFRERBB4KDREPHA2 | |
| SCHEMBL8554934 | 0.85 | ERBB2 (1.00) | ERBB2EGFRERBB4ABCG2 | |
| SCHEMBL31061496 | 0.85 | ERBB2 (1.00) | ERBB2EGFRERBB4ABCG2 | |
| Hydrochloric Acid SCHEMBL8597573 | 0.84 | ERBB2 (0.98) | ERBB2EGFRERBB4LCK | |
| SCHEMBL8555349 | 0.84 | ERBB2 (1.00) | ERBB2EGFRERBB4KDRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0843671-A1 | HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1998-05-27 | — | — | EP | claimed |
| WO-1997003069-A1 | HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1997-01-30 | — | — | WO | claimed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| US-20070191380-A1 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | IRM LLC (BM) | 2007-08-16 | — | — | US | disclosed |
| US-7176312-B2 | Kinase inhibitor scaffolds and methods for their preparation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-02-13 | — | — | US | disclosed |
| EP-0843671-A1 | HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997003069-A1 | HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191380-A1 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | MAP2K2, MAP2K1, MAP2K7 | ERBB2 54/4885EGFR 382/4885ERBB4 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.